Latest Ohio State University Comprehensive Cancer Center Stories
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL).
The Ohio State University Comprehensive Cancer Center and Moffitt Cancer Center create ORIEN to accelerate more precise cancer treatments, diagnostics and prevention methods TAMPA,
A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.
Human papillomavirus (HPV) can damage chromosomes and genes directly, researchers report in a new study.
Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL).
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia.
A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people with acute leukemia.
Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years.
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.